KLK3 and prostate cancer: Hefland [42] used the 4 PSA-SNPs to create personalized PSA cutoffs and to determine how many men would meet common biopsy criteria (PSA ≥2.5ng/mL and ≥4ng/mL) after genetic correction of their measured PSA level (n = 964 US Caucasian men without prostate cancer).